Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 25th Preview)
-
Regulatory approvals and evidence standards in rare disease
The FDA approved Denali Therapeutics’ Hunter syndrome medicine Avlayah, a decision that arrives amid a more stringent posture toward rare-disease evidence. The agency’s approval is notable because it recently rejected Regenxbio’s Hunter syndrome gene therapy over what it deemed insufficient clinical data. Denali’s approval underscores that sponsors still have a pathway to market when programs satisfy the agency’s current expectations for clinical support. The contrast with Regenxbio’s rejection highlights how underwriting standards are being applied across gene and rare-disease categories, with regulators signaling they may require more mature or higher-volume clinical evidence. For biotech leaders, the approval is a timely reminder to stress-test trial design, endpoints, and dataset depth against FDA expectations—especially in rare inherited disorders where regulatory decisions are increasingly scrutinizing the strength and breadth of data packages.
-
Rare disease RNA therapeutics—early clinical readouts reshape expectations
Sarepta Therapeutics shared preliminary clinical data that lifted sentiment around its next wave of RNA-based muscle disease programs, including SRP-1001 and SRP-1003. The company reported early evidence of safety and potential efficacy as it works to rebuild after setbacks around its Duchenne muscular dystrophy franchise. Separately, Sarepta also posted early success on Arrowhead Pharmaceuticals’ RNAi assets, adding another early dataset to its RNA strategy. Taken together, the updates suggest Sarepta is using multiple RNA modalities to hedge clinical risk and extend its runway in muscular dystrophy and related rare neuromuscular indications. Investors will watch for confirmatory updates later this year and pivotal timing in 2027, with the near-term goal being clearer differentiation versus prior RNA gene-therapy expectations and the ability to generate durable clinical signals.
-
Big Pharma M&A—Merck expands oncology with Terns acquisition
Merck agreed to buy Terns Pharmaceuticals for $6.7 billion in cash, aiming to secure TERN-701, an oral allosteric BCR::ABL tyrosine kinase inhibitor candidate in chronic myeloid leukemia. The deal values Terns at $53 per share and is expected to close in the second quarter, providing Merck a new asset ahead of Keytruda’s loss of exclusivity in 2028. Analysts framed the transaction as a strategic pipeline replenishment move, with TERN-701 positioned to challenge Novartis’ Scemblix franchise if ongoing development confirms differentiation. Terns’ program received orphan drug designation from the FDA and has shown efficacy and safety signals in early testing. The acquisition highlights how large oncology portfolios are still being rebuilt through late-stage clinical or differentiated-mechanism deals—particularly as competitive dynamics intensify in major leukemia categories.
-
Immunology deals—Gilead buys Ouro for $2B and targets autoimmune reset
Gilead Sciences is acquiring Ouro Medicines in a deal valued at $2.17 billion, adding a BCMAxCD3 T-cell engager to its inflammation and autoimmune pipeline. The transaction is front-loaded with $1.675 billion in cash upfront and contingent payments, with Galapagos expected to remain involved through advanced discussions tied to operating assets and development responsibilities. Gilead’s acquisition centers on OM336 (gamgertamig), currently in phase 1/2 testing for autoimmune hemolytic anemia and immune thrombocytopenia. The structure also reflects a cross-partner approach: Galapagos is expected to pick up development execution while Gilead retains worldwide commercialization rights outside China. The deal marks a deliberate push into antibody-driven “immune reset” strategies for autoimmune indications, reinforcing the broader industry momentum behind BCMA/CD3 immunology targets as differentiated immune-engaging platforms.
-
Clinical signals in oncology—Maze reports phase 2 kidney data while stock reacts
Maze Therapeutics released topline phase 2 results for its genetic kidney disease program MZE829, reporting an average 35.6% reduction in disease-related measures. The company’s readout put the candidate in the same target arena as Vertex’s kidney program, intensifying the competitive focus on efficacy and durability in genetic nephropathies. Despite early optimism from analysts about “best-in-class potential,” the stock sold off as investors weighed the strength and completeness of the dataset. The divergence underscores how rare-disease oncology progress can still be judged harshly when trial power, comparator context, or endpoint durability are unclear. Investors will look for further updates to confirm whether MZE829 can convert phase 2 promise into registrational-grade evidence and maintain momentum through the next development phase.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.